Should daily intermittent hemodialysis be done to eliminate Lyrica (pregabalin) in a patient with toxicity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Pregabalin Toxicity with Hemodialysis

For patients with pregabalin toxicity, intermittent hemodialysis should be performed as the first-line extracorporeal treatment to rapidly eliminate the drug and resolve symptoms.

Rationale for Hemodialysis in Pregabalin Toxicity

  • Pregabalin can be effectively removed by hemodialysis, with standard hemodialysis procedures resulting in approximately 50% clearance in 4 hours 1
  • Pregabalin has three key properties that make it highly amenable to removal by hemodialysis:
    • Relatively low molecular weight (159.23 Da)
    • Low volume of distribution (0.5 L/kg)
    • Not bound to plasma proteins 2
  • Documented hemodialysis clearance rates of 88.8 mL/min have been achieved, which correlates with rapid resolution of toxicity symptoms 2

Recommended Hemodialysis Protocol

  • Modality selection: Intermittent hemodialysis is strongly recommended as the preferred extracorporeal treatment modality 3
  • Timing: Initiate hemodialysis promptly upon diagnosis of significant pregabalin toxicity 1
  • Duration: Continue hemodialysis until clinical improvement is observed 3
  • Frequency: Daily intermittent hemodialysis sessions may be required until toxicity resolves 3

Optimizing Hemodialysis Parameters

  • Use higher blood flow rates and dialyzers with larger surface area to enhance clearance 3
  • Optimize dialysis parameters to reduce risk of hemodynamic compromise:
    • Prime the extracorporeal circuit appropriately
    • Consider lowering dialysate temperature
    • Use dialysate with appropriate electrolyte concentrations
    • Minimize net ultrafiltration if not clinically indicated 3, 4

Monitoring During and After Hemodialysis

  • Monitor vital signs and clinical status throughout the procedure 1
  • Assess for resolution of toxicity symptoms (reduced consciousness, confusion, agitation, seizures) 1
  • Consider serum drug concentration monitoring when available, though clinical improvement should be the primary endpoint 3, 5

When to Stop Hemodialysis

  • Base cessation of hemodialysis on clinical improvement rather than predetermined duration 3
  • Key indicators for stopping include:
    • Resolution of neurological symptoms
    • Hemodynamic stability
    • Absence of seizure activity 3

Important Considerations

  • Administer medications after hemodialysis sessions to avoid premature removal 3, 5
  • For patients on chronic hemodialysis who develop pregabalin toxicity, an additional non-scheduled hemodialysis session should be performed 2
  • Consult with nephrology for appropriate dialysis prescription and monitoring 3
  • Contact a Certified Poison Control Center for up-to-date management recommendations 1

Potential Complications and Mitigation

  • Hemodynamic instability during hemodialysis may occur, particularly in critically ill patients 4
  • Strategies to mitigate hemodynamic instability include:
    • Cooling the dialysate
    • Adjusting dialysate sodium concentration
    • Careful monitoring of ultrafiltration rates 4
  • Electrolyte disturbances may occur during rapid drug removal; monitor and correct as needed 3

References

Research

Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of Intermittent Hemodialysis in the Critically Ill Patient.

Clinical journal of the American Society of Nephrology : CJASN, 2023

Guideline

Pregabalin Dosing in Dialysis Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.